Phase I evaluation of SOAz (1,3,3,5,5 pentakis(aziridino)-1 lambda 6, 2,4,6,3 lambda 5, 5 lambda 5 thiatriaza-diphosphorine-1-oxide) in a weekly schedule.

Abstract

Eleven patients with advanced cancer were treated with SOAz, the first aziridino substituted inorganic heterocyclic compound to undergo phase I clinical trials. The agent was administered as a rapid i.v. infusion once a week in a dose of 50, 75 or 100 mg/m2. Severe myelotoxicity, which was prolonged and delayed in onset, precluded continuing treatment for more than three courses in 9 of 11 patients. In two patients thrombocytopenia showed no signs of recovery 9 and 11 weeks after the last infusion. Two minor responses were noted and there was one therapy-related death. Because of severe myelotoxicity, which is cumulative and may be irreversible, this treatment schedule seems unsuitable for phase II studies.

• Authors: S Rodenhuis, N H Mulder, D T Sleijfer, H Schraffordt Koops, J C Van de Grampel
• Journal: European journal of cancer & clinical oncology (Eur J Cancer Clin Oncol) Vol. 20 Issue 5 Pg. 645-9 (May 1984) ISSN: 0277-5379 [Print] England
• PMID: 6539701 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Azirines
• pentazirinocyclodiphosphathiazene

Topics

• Adult
• Aged
• Antineoplastic Agents (administration & dosage, therapeutic use, toxicity)
• Azirines (administration & dosage, therapeutic use, toxicity)
• Bone Marrow Diseases (chemically induced)
• Drug Administration Schedule
• Drug Evaluation
• Female
• Humans
• Male
• Middle Aged
• Neoplasms (drug therapy)
• Thrombocytopenia (chemically induced)